Tcr2 Therapeutics Inc

TCRR

NASDAQ. Currency in USD

1.14 -0.04 ( -3.39% )

Real time prices: December 09

Market Cap.
44.07M
Beta (5Y monthly)
1.70
Price/Earnings
-
EPS (TTM)
-3.09
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
454,553
1y Target Est.
11.67
Day's Range
1.12
-
1.19
52 Week's Range
1.12
-
5.26

Historical Summary

Performance
EPS growth
Share Buybacks

About Tcr2 Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.tcr2.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
38.22M
Employees
105
Address
100 Binney Street, Cambridge, MA, United States, 02142
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest news

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) --  TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...
By GlobeNewswire Inc. - 1 week ago

TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...
By GlobeNewswire Inc. - 2 weeks ago

Procter & Gamble To Jump Over 16%? Here Are 5 Other Price Target Changes For Monday
Procter & Gamble To Jump Over 16%? Here Are 5 Other Price Target Changes For Monday

Raymond James boosted The Procter & Gamble Company (NYSE: PG) price target from $155 to...
By Benzinga - 2 weeks ago

Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)
Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR)

TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure...
By Zacks Investment Research - 4 weeks ago

TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...
By GlobeNewswire Inc. - 4 weeks ago

TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...
By GlobeNewswire Inc. - 4 weeks ago

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...
By GlobeNewswire Inc. - 5 weeks ago

TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage...
By GlobeNewswire Inc. - 9 weeks ago